{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:24Z","timestamp":1793212164758,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40261-023-01252-z","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T06:47:42Z","timestamp":1680504462000},"page":"277-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02883452","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-4046","authenticated-orcid":false,"given":"Geert","family":"D\u2019Haens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-8148","authenticated-orcid":false,"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-6325","authenticated-orcid":false,"given":"Byong Duk","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-2432","authenticated-orcid":false,"given":"Dong-Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4690-6054","authenticated-orcid":false,"given":"SangWook","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-4580","authenticated-orcid":false,"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"issue":"4","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113(4):481\u2013517. https:\/\/doi.org\/10.1038\/ajg.2018.27.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14(1):4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"1252_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769\u201384. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx009.","journal-title":"J Crohns Colitis"},{"key":"1252_CR5","unstructured":"European Medicines Agency. Remicade: summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf. Accessed 24 Mar 2022."},{"key":"1252_CR6","unstructured":"US Food and Drug Administration. Remicade prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103772s5401lbl.pdf. Accessed 24 Mar 2022."},{"issue":"8","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.dld.2014.04.004","volume":"46","author":"C Duchesne","year":"2014","unstructured":"Duchesne C, Faure P, Kohler F, Pingannaud MP, Bonnaud G, Devulder F, et al. Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists. Dig Liver Dis. 2014;46(8):675\u201381. https:\/\/doi.org\/10.1016\/j.dld.2014.04.004.","journal-title":"Dig Liver Dis"},{"issue":"9","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","volume":"40","author":"JE Brady","year":"2018","unstructured":"Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40(9):1509\u201321.e5. https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.013.","journal-title":"Clin Ther"},{"issue":"7","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cgh.2015.02.017","volume":"13","author":"MT Osterman","year":"2015","unstructured":"Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger CM, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015;13(7):1293\u2013301.e5. https:\/\/doi.org\/10.1016\/j.cgh.2015.02.017.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.cgh.2015.06.034","volume":"13","author":"JL Jones","year":"2015","unstructured":"Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn\u2019s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13(13):2233\u201340.e2. https:\/\/doi.org\/10.1016\/j.cgh.2015.06.034.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","volume":"30","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210\u201326. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04027.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/gut.2010.212712","volume":"59","author":"H Sokol","year":"2010","unstructured":"Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59(10):1363\u20138. https:\/\/doi.org\/10.1136\/gut.2010.212712.","journal-title":"Gut"},{"issue":"8","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","volume":"63","author":"B Ungar","year":"2014","unstructured":"Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63(8):1258\u201364. https:\/\/doi.org\/10.1136\/gutjnl-2013-305259.","journal-title":"Gut"},{"issue":"15","key":"1252_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362(15):1383\u201395. https:\/\/doi.org\/10.1056\/NEJMoa0904492.","journal-title":"N Engl J Med"},{"issue":"8","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/apt.13139","volume":"41","author":"JF Colombel","year":"2015","unstructured":"Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, et al. Randomised clinical trial: deep remission in biologic and immunomodulator na\u00efve patients with Crohn\u2019s disease\u2014a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41(8):734\u201346. https:\/\/doi.org\/10.1111\/apt.13139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1252_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione R, Ghosh S, Middleton S, M\u00e1rquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392\u2013400.e3. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.052.","journal-title":"Gastroenterology"},{"issue":"5","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341\u201353. https:\/\/doi.org\/10.1016\/s2468-1253(19)30012-3.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"8","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","volume":"17","author":"JF Colombel","year":"2019","unstructured":"Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D\u2019Haens GR, et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clin Gastroenterol Hepatol. 2019;17(8):1525\u201332.e1. https:\/\/doi.org\/10.1016\/j.cgh.2018.09.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1252_CR19","unstructured":"European Medicines Agency. Remsima: assessment report on extension(s) of marketing authorisation. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/remsima-h-c-2576-x-0062-epar-assessment-report-variation_en.pdf. Accessed 24 Mar 2022."},{"key":"1252_CR20","unstructured":"BusinessWire. Celltrion Healthcare receives EU marketing authorisation for world\u2019s first subcutaneous formulation of infliximab, Remsima SC\u2122, for the treatment of people with rheumatoid arthritis. 2019. https:\/\/www.businesswire.com\/news\/home\/20191125005867\/en\/Celltrion-Healthcare-receives-EU-marketing-authorisation-for-world%E2%80%99s-first-subcutaneous-formulation-of-infliximab-Remsima-SC%E2%84%A2-for-the-treatment-of-people-with-rheumatoid-arthritis. Accessed 24 Mar 2022."},{"key":"1252_CR21","unstructured":"European Medicines Agency. Remsima: extension of indication variation assessment report. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/remsima-h-c-2576-ii-0082-epar-assessment-report-variation_en.pdf. Accessed 24 Mar 2022."},{"issue":"7","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340\u201353. https:\/\/doi.org\/10.1053\/j.gastro.2021.02.068.","journal-title":"Gastroenterology"},{"issue":"7","key":"1252_CR23","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.autrev.2021.102849","volume":"20","author":"F D'Amico","year":"2021","unstructured":"D\u2019Amico F, Solitano V, Aletaha D, Hart A, Magro F, Selmi C, et al. Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus. Autoimmun Rev. 2021;20(7):102849. https:\/\/doi.org\/10.1016\/j.autrev.2021.102849.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"1868078","DOI":"10.1080\/19420862.2020.1868078","volume":"13","author":"H Kim","year":"2021","unstructured":"Kim H, Alten R, Cummings F, Danese S, D\u2019Haens G, Emery P, et al. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs. 2021;13(1):1868078. https:\/\/doi.org\/10.1080\/19420862.2020.1868078.","journal-title":"MAbs"},{"issue":"8S","key":"1252_CR25","first-page":"A90","volume":"6","author":"S Ben-Horin","year":"2018","unstructured":"Ben-Horin S, Reinisch W, Ye BD, Westhovens R, Yoo DH, Lee SJ, et al. OP234\u2014development of a subcutaneous formulation of CT-P13 (infliximab): maintenance subcutaneous administration may elicit lower immunogenicity compared to intravenous treatment. United European Gastroenterol J. 2018;6(8S):A90\u20131.","journal-title":"United European Gastroenterol J."},{"key":"1252_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4939-9591-2_7","volume":"2020","author":"WP Stefura","year":"2019","unstructured":"Stefura WP, Graham C, Lotoski L, HayGlass KT. Improved methods for quantifying human chemokine and cytokine biomarker responses: ultrasensitive ELISA and Meso Scale electrochemiluminescence assays. Methods Mol Biol. 2019;2020:91\u2013114. https:\/\/doi.org\/10.1007\/978-1-4939-9591-2_7.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"1252_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, Gerson L, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827\u201334. https:\/\/doi.org\/10.1053\/j.gastro.2017.07.032.","journal-title":"Gastroenterology"},{"issue":"3","key":"1252_CR28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cgh.2014.07.027","volume":"13","author":"D Drobne","year":"2015","unstructured":"Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015;13(3):514\u201321.e4. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.027.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1252_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.cgh.2014.09.031","volume":"13","author":"W Reinisch","year":"2015","unstructured":"Reinisch W, Colombel JF, Sandborn WJ, Mantzaris GJ, Kornbluth A, Adedokun OJ, et al. Factors associated with short- and long-term outcomes of therapy for Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015;13(3):539\u201347.e2. https:\/\/doi.org\/10.1016\/j.cgh.2014.09.031.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1252_CR30","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/ibd\/izy010","volume":"24","author":"LY Chi","year":"2018","unstructured":"Chi LY, Zitomersky NL, Liu E, Tollefson S, Bender-Stern J, Naik S, et al. The impact of combination therapy on infliximab levels and antibodies in children and young adults with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(6):1344\u201351. https:\/\/doi.org\/10.1093\/ibd\/izy010.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1252_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/ecco-jcc\/jjw216","volume":"11","author":"V Razanskaite","year":"2017","unstructured":"Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw216.","journal-title":"J Crohns Colitis"},{"key":"1252_CR32","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.jtauto.2019.100004","volume":"1","author":"M El Amrani","year":"2019","unstructured":"El Amrani M, Gobel C, Egas AC, Nierkens S, Hack CE, Huitema ADR, et al. Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: infliximab as proof of principle. J Transl Autoimmun. 2019;1:100004. https:\/\/doi.org\/10.1016\/j.jtauto.2019.100004.","journal-title":"J Transl Autoimmun."},{"key":"1252_CR33","doi-asserted-by":"publisher","first-page":"1756283X1775035","DOI":"10.1177\/1756283X17750355","volume":"11","author":"S Vermeire","year":"2018","unstructured":"Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. https:\/\/doi.org\/10.1177\/1756283X17750355.","journal-title":"Therap Adv Gastroenterol."},{"key":"1252_CR34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","volume":"11","author":"S Atiqi","year":"2020","unstructured":"Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-inhibitors. Front Immunol. 2020;11:312. https:\/\/doi.org\/10.3389\/fimmu.2020.00312.","journal-title":"Front Immunol"},{"issue":"17","key":"1252_CR35","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679\u201386. https:\/\/doi.org\/10.1001\/jama.2017.16071.","journal-title":"JAMA"},{"issue":"2","key":"1252_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337\u201346.e10. https:\/\/doi.org\/10.1053\/j.gastro.2018.04.012.","journal-title":"Gastroenterology"},{"key":"1252_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/CEG.S237646","volume":"13","author":"J Dahmus","year":"2020","unstructured":"Dahmus J, Rosario M, Clarke K. Risk of lymphoma associated with anti-TNF therapy in patients with inflammatory bowel disease: implications for therapy. Clin Exp Gastroenterol. 2020;13:339\u201350. https:\/\/doi.org\/10.2147\/CEG.S237646.","journal-title":"Clin Exp Gastroenterol"},{"issue":"18","key":"1252_CR38","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.2165\/0003495-200868180-00006","volume":"68","author":"SV Kane","year":"2008","unstructured":"Kane SV. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs. 2008;68(18):2601\u20139. https:\/\/doi.org\/10.2165\/0003495-200868180-00006.","journal-title":"Drugs"},{"issue":"10","key":"1252_CR39","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.dld.2016.06.036","volume":"48","author":"F Casellas","year":"2016","unstructured":"Casellas F, Ginard D, Riestra S. Patient satisfaction in the management of mild-to-moderate ulcerative colitis: results of a Delphi study among patients and physicians. Dig Liver Dis. 2016;48(10):1172\u20139. https:\/\/doi.org\/10.1016\/j.dld.2016.06.036.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"1252_CR40","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","volume":"70","author":"RC Ungaro","year":"2021","unstructured":"Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70(4):725\u201332. https:\/\/doi.org\/10.1136\/gutjnl-2020-322539.","journal-title":"Gut"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01252-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01252-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01252-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:26:14Z","timestamp":1681313174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01252-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01252-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"16 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This post hoc analysis was funded in full by Celltrion Healthcare Co., Ltd (Incheon, Republic of Korea). Medical writing support for this article was funded by Celltrion Healthcare Co., Ltd. Open access funding was provided by Celltrion Healthcare Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Geert D\u2019Haens has served as a speaker for AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Celltrion, Eli Lilly, Galapagos, Immunic, Johnson and Johnson, and Pfizer; served on a Data Safety Monitoring Board for AbbVie, Ablynx, Allergan, AstraZeneca, Galapagos, GlaxoSmithKline, and Seres Health; served as a consultant for AbbVie, Agomab, AM Pharma, AMT, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Gilead, GlaxoSmithKline, Gossamerbio, Immunic, Index Pharmaceuticals, Johnson and Johnson, Kaleido, Origo, Pfizer, Polpharma, Procise Diagnostics, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist, and Roche; and received grants or contracts from AbbVie, Bristol Myers Squibb, Helmsley Foundation, Pfizer, and Takeda. Walter Reinisch has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Celltrion, Falk Pharma, Ferring, Janssen, Medice, Mitsubishi Tanabe Pharma Corporation, MSD, Pfizer, Pharmacosmos, PLS Education, Roche, Shire, Takeda, Therakos, and Vifor; served as a consultant for AbbVie, Algernon, Amgen, Arena Pharmaceuticals, Astellas, AstraZeneca, Bioclinica, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Celgene, Celltrion, Eli Lilly, Ernst & Young, Falk Pharma, Ferring, Fresenius, Galapagos, Gatehouse Bio, Genentech, Gilead, Gr\u00fcnenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Landos Biopharma, LivaNova, Mallinckrodt, Medahead, MedImmune, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Novartis, OMass, Otsuka, Parexel, Periconsulting, Pfizer, Pharmacosmos, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Roche, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpoint Medical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Vifor, and Zealand; received support for attending meetings and\/or travel from AbbVie, Janssen, and Takeda; and served on a Data Safety Monitoring Board or advisory board for OSE Pharma. Stefan Schreiber has served as a consultant or advisory board member for AbbVie, Amgen, Arena, Bristol Myers Squibb, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Galapagos, Gilead, IMAB, Janssen, Lilly, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz\/Hexal, Takeda, Theravance, and UCB. Fraser Cummings has served as a consultant for AbbVie, Amgen, Biogen, Bristol Myers Squibb, Galapagos, Janssen, Samsung Bioepis, and Tillots; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Amgen, Biogen, Dr Falk, Galapagos, Janssen, Pfizer, Pharmacosmos, and Tillots; received support for attending meetings and\/or travel from Janssen and Tillots; received grants for conducting investigator-initiated studies from Biogen, Celltrion, and Janssen; and is a member of the British Society of Gastroenterology IBD section (unpaid) and is the UK IBD registry clinical lead (paid). Peter M. Irving has served as a consultant for AbbVie and Bristol Myers Squibb; received lecture fees from AbbVie, Bristol Myers Squibb, Celgene, Celltrion, Falk Pharma, Galapagos, Janssen, Lilly, Pfizer, and Takeda; served on Data Safety Monitoring Boards or advisory boards for AbbVie, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Prometheus, Roche, Sandoz, Samsung Bioepis, and Takeda; and received financial support for research from Celltrion, Galapagos, Pfizer, and Takeda. Byong Duk Ye has served on advisory boards for AbbVie Korea, Celltrion, Daewoong Pharma, Ferring Korea, Janssen Korea, Organoid Sciences Ltd, Pfizer Korea, Takeda, and Takeda Korea; served as a consultant for Chong Kun Dang Pharm., CJ Red BIO, Daewoong Pharma, Kangstem Biotech, Korea Otsuka Pharm, Korea United Pharm. Inc., Medtronic Korea, NanoEntek, Organoid Sciences Ltd, and Takeda; received speaker fees from AbbVie Korea, Celltrion, Curacle, Ferring Korea, IQVIA, Janssen Korea, Pfizer Korea, Takeda, and Takeda Korea; and received research grants from Celltrion and Pfizer Korea. Dong-Hyeon Kim and SangWook Yoon are employees of and hold stock or stock options in Celltrion Healthcare Co., Ltd. Shomron Ben-Horin has served as a consultant or advisory board member for AbbVie, Celltrion, Falk, Ferring, Galmed, GSK, Janssen, Novartis, Pfizer, and Takeda; and received research support from AbbVie, Celltrion, Galmed, Janssen, Pfizer, and Takeda.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The data underlying this article are available in the article and in its online supplementary material. The individual participant data cannot be shared publicly for the privacy of individuals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This post hoc analysis is based on the primary study (NCT02883452) that was conducted according to International Council for Harmonisation guidelines and following the principles of the Declaration of Helsinki and all applicable national, state, and local laws. The protocol and written study materials were approved by institutional review boards\/independent ethics committees prior to study initiation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"GD\u2019H: Conceptualisation (lead), methodology (lead), supervision (lead), visualisation (equal), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). WR: conceptualisation (equal), methodology (equal), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). SS: conceptualisation (equal), methodology (equal), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). FC: conceptualisation (equal), methodology (equal), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). PMI: conceptualisation (equal), methodology (equal), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). BDY: conceptualisation (equal), methodology (equal), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). D-HK: conceptualisation (equal), formal analysis (lead), methodology (equal), validation (lead), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). SWY: conceptualisation (equal), formal analysis (lead), methodology (equal), validation (lead), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). SB-H: conceptualisation (lead), methodology (lead), supervision (lead), visualisation (equal), writing\u2014original draft (equal), and writing\u2014reviewing and editing (equal). All authors had access to the post hoc analysis data and contributed to manuscript drafting, critical review, and revision. All authors approved the final manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}